Wockhardt has reported results for fourth quarter and year ended March 31, 2012.
On the standalone basis, the company has reported net loss of Rs 68.64 crore for the quarter ended March 31, 2012, against net profit of Rs 32.25 crore for the corresponding period last fiscal. However, total income increased by 68.90% at Rs 722.93 crore during the quarter under review from Rs 428.03 crore in the year-ago period.
On the consolidated basis, the company has reported net loss of Rs 191.64 crore for the quarter ended March 31, 2012, against net profit of Rs 161.83 crore for the corresponding period last fiscal. However, total income increased by 32.63% at Rs 1248.13 crore during the quarter under review from Rs 941.03 crore in the year-ago period.
For the full year ended March 31, 2012, the company has reported net profit of Rs 184.00 crore for the year ended March 31, 2012, against net loss of Rs 132.07 crore for the corresponding period last fiscal. Total income increased by 45.63% at Rs 2580.52 crore during the year under review from Rs 1772.01 crore in the year-ago period.
On the consolidated basis, the company has posted a rise of 278.60% in its net profit at Rs 342.71 crore for the year ended March 31, 2012 as compared to Rs 90.52 crore for the same period in the previous year. Total income has increased by 23.08% at Rs 4637.26 crore for year under review as compared to Rs 3767.14 crore for the period ended March 31, 2011.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |